Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ascendis Pharma ADR
(NQ:
ASND
)
138.84
-0.66 (-0.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ascendis Pharma ADR
< Previous
1
2
3
4
5
6
Next >
Expert Ratings For Ascendis Pharma
March 07, 2022
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
March 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis...
Via
Benzinga
Pfizer Dives After FDA Rejects Its OPKO-Partnered Rare Disease Treatment
January 24, 2022
Pfizer stock tumbled after the FDA rejected an OPKO-partnered drug.
Via
Investor's Business Daily
Ascendis Pharma's Growth Hormone Deficiency Med Scores European Approval
January 13, 2022
The European Commission (EC) has granted marketing authorization to Ascendis Pharma A/S's (NASDAQ: ASND) Lonapegsomatropin (developed under the name TransCon hGH)....
Via
Benzinga
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
November 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack...
Via
Benzinga
Analyst Ratings For Ascendis Pharma
November 11, 2021
Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND
Via
Benzinga
Earnings Scheduled For March 2, 2022
March 02, 2022
Companies Reporting Before The Bell • SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. •...
Via
Benzinga
Where Ascendis Pharma Stands With Analysts
January 27, 2022
Over the past 3 months, 4 analysts have published their opinion on Ascendis Pharma (NASDAQ:ASND) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
Where Ascendis Pharma Stands With Analysts
January 06, 2022
Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
March 01, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...
Via
Benzinga
Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks
November 19, 2021
Ascendis Pharma A/S (NASDAQ: ASND) announced topline results from Week 84 of its Phase 2 PaTH Forward Trial of its TransCon PTH candidate hypoparathyroidism (HP)....
Via
Benzinga
10 Biggest Price Target Changes For Monday
November 15, 2021
Keybanc boosted the price target on Netflix, Inc. (NASDAQ: NFLX) from $690 to $725. Netflix shares rose 0.2% to $683.90 in pre-market trading. Piper Sandler raised the price...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022
February 14, 2022
Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,...
Via
Benzinga
Ascendis Pharma A/S (ASND) Q3 2021 Earnings Call Transcript
November 10, 2021
ASND earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
January 06, 2022
Upgrades For Canada Goose Holdings Inc (NYSE:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
December 08, 2021
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD...
Via
Benzinga
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More
October 03, 2021
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding...
Via
Talk Markets
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021
October 20, 2021
Upgrades For Iridium Communications Inc (NASDAQ:IRD...
Via
Benzinga
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
October 03, 2021
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co...
Via
Benzinga
Exposures
Product Safety
Pfizer's Growth Hormone Candidate FDA Review Pushed By 3 Months
September 27, 2021
Pfizer Inc's (NYSE: PFE) effort to defend its growth hormone franchise against a new, more convenient competitor has hit a snag. The FDA has pushed back...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
September 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (...
Via
Benzinga
Exposures
COVID-19
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August 31, 2021
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New...
Via
Benzinga
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
September 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In A Light Week
August 29, 2021
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. and BioNTech SE. The stocks subsequently moved back and...
Via
Talk Markets
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
September 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU...
Via
Benzinga
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week
August 29, 2021
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. (NYSE: PFE) and BioNTech SE (...
Via
Benzinga
Ascendis Pharma A/S (ASND) Q2 2021 Earnings Call Transcript
August 28, 2021
ASND earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
63 Biggest Movers From Yesterday
August 27, 2021
Gainers Support.com, Inc. (NASDAQ: SPRT) shares surged 41.1% to settle at $19.70 on Thursday on abnormally high volume. TSR, Inc. (NASDAQ: TSRI) shares rose 28.1% to close at $11...
Via
Benzinga
Why Shares of Ascendis Soared This Week
August 26, 2021
The pharmaceutical company saw its shares jump more than $26.
Via
The Motley Fool
Mid-Afternoon Market Update: Pure Storage Rises Following Strong Q2 Results; SelectQuote Shares Plunge
August 26, 2021
Toward the end of trading Thursday, the Dow traded down 0.38% to 35,270.96 while the NASDAQ fell 0.35% to 14,988.64. The S&P also fell, dropping 0.40% to 4,483.22. The U.S....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.